Although the United States and numerous other countries are amidst an opioid overdose crisis, access to safe injection facilities remains limited.
Methods
We used prospective data from ambulance journals in Oslo, Norway, to describe the patterns, severity, and outcomes of opioid overdoses and compared these characteristics among various overdose locations. We also examined what role a safe injection facility may have had on these overdoses.
Results
Based on 48,825 ambulance calls, 1054 were for opioid overdoses from 465 individuals during 2014 and 2015. The rate of calls for overdoses was 1 out of 48 of the total ambulance calls. Males made up the majority of the sample (n = 368, 79%), and the median age was 35 (range: 18–96). Overdoses occurred in public locations (n = 530, 50.3%), the safe injection facility (n = 353, 33.5%), in private homes (n = 83, 7.9%), and other locations (n = 88, 8.3%). Patients from the safe injection facility and private homes had similarly severe initial clinical symptoms (Glasgow Coma Scale median =3 and respiratory frequency median =4 breaths per minute) when compared with other locations, yet the majority from the safe injection facility did not require further ambulance transport to the hospital (n = 302, 85.6%). Those overdosed in public locations (odds ratio [OR] = 1.66, 95% confidence interval [CI] = 1.17–2.35), and when the safe injection facility was closed (OR =1.4, 95% CI =1.04–1.89), were more likely to receive transport for further treatment.
Conclusions
Our findings suggest that the opening hours at the safe injection facility and the overdose location may impact the likelihood of ambulance transport for further treatment.
UNODC. World Drug Report 2016. United Nations Office on Drugs and Crime; 2016.
2.
RuddRA, AleshireN, ZibbellJE, GladdenRM. Increases in drug and opioid overdose deaths-United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378–1382.
3.
HallAJ, LoganJE, ToblinRL, . Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA2008;300(22):2613–2620.
4.
HanB, ComptonWM, JonesCM, CaiR. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA2015;314(14):1468–1478.
5.
Madah-AmiriD, ClausenT, MyrmelL, BratteboG, LobmaierP. Circumstances surrounding non-fatal opioid overdoses attended by ambulance services. Drug Alcohol Rev. 2017;36(3):288–294.
6.
European Drug Report2015. European Monitoring Centre for Drugs and Drug Addiction; 2015.
7.
GjersingL, JonassenKV, BiongS, . Diversity in causes and characteristics of drug-induced deaths in an urban setting. Scand J Public Health. 2013;41(2):119–125.
8.
AmundsenEJ, Bretteville-JensenAL. Hard drug use in Norway. Nordisk Alkohol- & Narkotikatidskrift. 2010;27(1):87.
9.
MurthyVH. Surgeon general's report on alcohol, drugs, and health. JAMA2017;317(2):133–134.
10.
MurthyVH. Ending the opioid epidemic - a call to action. N Engl J Med. 2016;375(25):2413–2415.
11.
Reports of the Surgeon General. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington (DC): US Department of Health and Human Services; 2016.
12.
RhodesT, HedrichD. Harm Reduction: Evidence, Impacts and Challenges. Spain: Publiations Office of the Europen Union; 2010.
13.
KennedyMC, KaramouzianM, KerrT. Public health and public order outcomes associated with supervised drug consumption facilities: a systematic review. Curr HIV/AIDS Rep2017;14(5):161–183.
14.
PotierC, LaprevoteV, Dubois-ArberF, CottencinO, RollandB. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68.
15.
MarshallBD, MilloyMJ, WoodE, MontanerJS, KerrT. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–1437.
16.
WoodE, TyndallMW, LiK, . Do supervised injecting facilities attract higher-risk injection drug users?Am J Prev Med. 2005;29(2):126–130.
17.
KerrT, TyndallM, LiK, MontanerJ, WoodE. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;366(9482):316–318.
18.
WoodE, KerrT, SmallW, . Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004;171(7):731–734.
19.
WoodE, TyndallMW, ZhangR, MontanerJS, KerrT. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007;102(6):916–919.
20.
DeBeckK, KerrT, BirdL, . Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug Alcohol Depend. 2011;113(2-3):172–176.
21.
KinnardEN, HoweCJ, KerrT, Skjodt HassV, MarshallBD. Self-reported changes in drug use behaviors and syringe disposal methods following the opening of a supervised injecting facility in Copenhagen, Denmark. Harm Reduct J. 2014;11(1):29.
22.
SalmonAM, van BeekI, AminJ, KaldorJ, MaherL. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction. 2010;105(4):676–683.
23.
HathawayAD, TousawKI. Harm reduction headway and continuing resistance: insights from safe injection in the city of Vancouver. Int J Drug Policy. 2008;19(1):11–16.
24.
BeletskyL, DavisCS, AndersonE, BurrisS. The law (and politics) of safe injection facilities in the United States. Am J Public Health. 2008;98(2):231–237.
25.
RhodesT, WattsL, DaviesS, . Risk, shame and the public injector: a qualitative study of drug injecting in South Wales. Soc Sci Med. 2007;65(3):572–585.
26.
RhodesT, KimberJ, SmallW, . Public injecting and the need for ‘safer environment interventions’ in the reduction of drug-related harm. Addiction. 2006;101(10):1384–1393.
27.
GjersingL, JonassenK, SkurtveitS, BramnessJ, ClausenT. Emergency service use is common in the year before death among drug users who die from an overdose. J Subst Use. 2017;22(3):331–336.
28.
Vanden HoekTL, MorrisonLJ, ShusterM, . Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18_suppl_3):S829–S861.
29.
Madah-AmiriD, ClausenT, LobmaierP. Rapid widespread distribution of intranasal naloxone for overdose prevention. Drug Alcohol Depend. 2017;173:17–23.
30.
TeasdaleG, MaasA, LeckyF, ManleyG, StocchettiN, MurrayG. The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol. 2014;13(8):844–854.
31.
MilloyMJ, KerrT, MathiasR, . Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse. 2008;34(4):499–509.
32.
KerrT, FairbairnN, TyndallM, . Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87(1):39–45.
33.
DarkeS, KayeS, RossJ. Geographical injecting locations among injecting drug users in Sydney, Australia. Addiction. 2001;96(2):241–246.
34.
MarshallBD, KerrT, QiJ, MontanerJS, WoodE. Public injecting and HIV risk behaviour among street-involved youth. Drug Alcohol Depend. 2010;110(3):254–258.
35.
Madah-AmiriD, ClausenT, LobmaierP. Utilizing a train-the-trainer model for multi-site naloxone distribution programs. Drug Alcohol Depend. 2016;163:153–156.
36.
HeyerdahlF, HovdaKE, BjornaasMA, . Pre-hospital treatment of acute poisonings in Oslo. BMC Emerg Med. 2008;8(1),
37.
WillmanMW, LissDB, SchwarzES, MullinsME. Do heroin overdose patients require observation after receiving naloxone?Clin Toxicol (Phila). 2016;55(2):81–87.
38.
WamplerDA, MolinaDK, McManusJ, LawsP, ManifoldCA. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care. 2011;15(3):320–324.
39.
KerrT, StoltzJ-A, TyndallM, . Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ. 2006;332(7535):220–222.
40.
WoodRA, WoodE, LaiC, TyndallMW, MontanerJS, KerrT. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility. Int J Drug Policy. 2008;19(3):183–188.
